Grünenthal, a science-based, fully integrated pharmaceutical company, agreed to acquire Valinor Pharma, a pharmaceutical company focused on innovative commercialization of medicines, for $250m. "As a pain specialist, Movantik is a perfect fit for Grünenthal with our existing customer base and complementary product portfolio. The acquisition of Valinor Pharma strengthens our footprint in the United States, the most important growth market for Grünenthal," Gabriel Baertschi, Grünenthal CEO.